Albumin-Based Cryogels as Floating Platforms for Gastroretentive Drug Delivery Applications
Authors:
Open Access
- 13 August 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (33) , 37639-37649
Abstract
Gastroretentive drug delivery systems (GRDDS) are attractive oral extended-release dosage forms that prolong drug release and absorption in the gastrointestinal tract through engineered mechanisms to extend the residence time of orally administered dosage forms in the stomach. One of the gastroretentive designs is to render the dosage forms floatable in the gastric fluid upon oral administration. The present study aimed to develop albumin cryogels with extended buoyancy and remarkable resistance to gastric proteolysis. Protein hydrogel monoliths can be prepared through thiol-organosilane-mediated hydrogelation of bovine serum albumin, followed by lyophilization to remove water, thereby producing cryogels. The study demonstrates that, by adjusting the composition of Na2HPO4 and sodium alginate in the hydrogel formulation, protein degradability can be effectively tuned to produce an intact floating structure with sustained buoyancy for over 24 h in simulated gastric fluid. This result is consistent with the finding that fluorescein, as a model payload, generally exhibited a decreased release rate from the formulations with increasing concentrations of Na2HPO4 and alginate. Notably, above a threshold concentration (i.e., about 2%) of alginate, the hydrogel monolith rapidly disintegrated in nearly neutral environments such as water and simulated intestinal fluid, exhibiting pH-responsive characteristics. Finally, the generalizability of the albumin-organosilane-alginate system as a promising controlled-release platform is further demonstrated in expanded application examples, using doxorubicin, mitoxantrone, methylene blue, and rhodamine 6G as the loaded payload; all exhibiting reproducible controlled-release profiles for the alginate-doped formulation. This finding can be explained by the SEM images showing smaller and denser porous structures with thicker, fiber-tangled intercompartment walls for gels with high alginate concentrations. Overall, the freeze-dried albumin-organosilane-alginate cryogel formulation demonstrates excellent buoyancy, resistance to degradation by simulated gastric fluid, and the ability to regulate drug release, highlighting its feasibility as a GRDDS.Keywords
Funding Information
- National Science and Technology Council (MOST 108-2320-B-010-037-MY3, MOST 111-2320-B-A49-020-MY3)
This publication has 45 references indexed in Scilit:
- Industrial perspective of gastroretentive drug delivery systems: Physicochemical, biopharmaceutical, technological and regulatory considerationExpert Opinion on Drug Delivery, 2012
- DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution ProfilesThe AAPS Journal, 2010
- Mathematical modeling of drug deliveryInternational Journal of Pharmaceutics, 2008
- Gastroretentive drug delivery systemsExpert Opinion on Drug Delivery, 2006
- Inhibition of pepsin activity by alginates in vitro and the effect of epimerizationInternational Journal of Pharmaceutics, 2005
- Floating drug delivery systems: A reviewAAPS PharmSciTech, 2005
- Modeling and comparison of dissolution profilesEuropean Journal of Pharmaceutical Sciences, 2001
- Use of floating alginate gel beads for stomach-specific drug deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Floating dosage forms: an in vivo study demonstrating prolonged gastric retentionJournal of Controlled Release, 1998
- A Floating Controlled-Release Drug Delivery System: In Vitro-in Vivo EvaluationPharmaceutical Research, 1993